[go: up one dir, main page]

NO20081125L - Antitumor middel - Google Patents

Antitumor middel

Info

Publication number
NO20081125L
NO20081125L NO20081125A NO20081125A NO20081125L NO 20081125 L NO20081125 L NO 20081125L NO 20081125 A NO20081125 A NO 20081125A NO 20081125 A NO20081125 A NO 20081125A NO 20081125 L NO20081125 L NO 20081125L
Authority
NO
Norway
Prior art keywords
antitumor agent
compound
cholestanol
sugar
exhibits
Prior art date
Application number
NO20081125A
Other languages
English (en)
Norwegian (no)
Inventor
Shin Yazawa
Touyou Nishimura
Takashi Nakagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20081125L publication Critical patent/NO20081125L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO20081125A 2005-09-02 2008-03-04 Antitumor middel NO20081125L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005255517 2005-09-02
PCT/JP2006/317316 WO2007026869A1 (ja) 2005-09-02 2006-09-01 抗癌剤

Publications (1)

Publication Number Publication Date
NO20081125L true NO20081125L (no) 2008-05-16

Family

ID=37808952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081125A NO20081125L (no) 2005-09-02 2008-03-04 Antitumor middel

Country Status (23)

Country Link
US (1) US7968116B2 (ja)
EP (1) EP1921086B1 (ja)
JP (1) JP5011113B2 (ja)
KR (1) KR101292539B1 (ja)
CN (1) CN101253192B (ja)
AR (1) AR057793A1 (ja)
AU (1) AU2006285678B2 (ja)
BR (1) BRPI0615196A2 (ja)
CA (1) CA2621377C (ja)
CY (1) CY1115196T1 (ja)
DK (1) DK1921086T3 (ja)
ES (1) ES2459767T3 (ja)
HR (1) HRP20140439T1 (ja)
IL (1) IL189752A (ja)
MY (1) MY155903A (ja)
NO (1) NO20081125L (ja)
PL (1) PL1921086T3 (ja)
PT (1) PT1921086E (ja)
RU (1) RU2410389C2 (ja)
SI (1) SI1921086T1 (ja)
TW (1) TWI373473B (ja)
WO (1) WO2007026869A1 (ja)
ZA (1) ZA200802813B (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
TWI492759B (zh) 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
NZ594996A (en) * 2009-03-04 2014-02-28 Otsuka Pharma Co Ltd Cholestanol derivative for combined use
WO2010113983A1 (ja) * 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
MA33127B1 (fr) 2009-03-30 2012-03-01 Eisai R&D Man Co Ltd Composition liposomique
JP6187942B2 (ja) 2012-03-02 2017-08-30 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 二重複合活性化による強力な抗癌活性
CA2866020C (en) 2012-03-06 2020-09-22 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
CN104507479B (zh) 2012-03-06 2017-08-18 伊利诺伊大学评议会 通过联合治疗的半胱天冬酶‑3酶原激活
CN103349948B (zh) * 2013-06-21 2015-05-27 江南大学 一种植物甾烷醇微胶囊化方法
CN105753923B (zh) * 2014-12-17 2017-09-29 富力 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572300A (en) 1980-06-09 1982-01-07 Tetsuo Suami Novel nitrosourea derivative
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
JP4105258B2 (ja) * 1997-08-19 2008-06-25 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
JPH11160592A (ja) 1997-11-28 1999-06-18 Hitachi Cable Ltd 光ファイバケーブル用スペーサ
JP4351314B2 (ja) * 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
CN1822844B (zh) 2003-07-17 2012-05-09 大塚制药株式会社 含配糖物的脂质体
CA2549074A1 (en) * 2003-12-18 2005-06-30 Unibioscreen S.A. Glycosylated steroid derivatives with anti-migratory activity
JP2005225822A (ja) * 2004-02-13 2005-08-25 Konica Minolta Medical & Graphic Inc リポソーム含有x線造影剤
KR100603814B1 (ko) * 2004-03-11 2006-07-25 바이오스펙트럼 주식회사 나노리포좀 조성물

Also Published As

Publication number Publication date
RU2410389C2 (ru) 2011-01-27
TWI373473B (en) 2012-10-01
CY1115196T1 (el) 2017-01-04
JP5011113B2 (ja) 2012-08-29
AU2006285678A1 (en) 2007-03-08
AU2006285678B2 (en) 2012-01-19
CA2621377C (en) 2013-10-22
PT1921086E (pt) 2014-04-29
MY155903A (en) 2015-12-15
ES2459767T3 (es) 2014-05-12
DK1921086T3 (da) 2014-05-05
HRP20140439T1 (hr) 2014-06-20
US20100292176A1 (en) 2010-11-18
IL189752A (en) 2013-07-31
CN101253192B (zh) 2011-05-04
CN101253192A (zh) 2008-08-27
TW200738744A (en) 2007-10-16
ZA200802813B (en) 2009-10-28
CA2621377A1 (en) 2007-03-08
EP1921086A4 (en) 2012-07-25
EP1921086B1 (en) 2014-04-16
RU2008112676A (ru) 2009-10-10
JPWO2007026869A1 (ja) 2009-03-12
BRPI0615196A2 (pt) 2011-05-10
WO2007026869A1 (ja) 2007-03-08
US7968116B2 (en) 2011-06-28
EP1921086A1 (en) 2008-05-14
PL1921086T3 (pl) 2014-09-30
SI1921086T1 (sl) 2014-05-30
KR101292539B1 (ko) 2013-08-20
HK1115140A1 (en) 2008-11-21
KR20080043838A (ko) 2008-05-19
AR057793A1 (es) 2007-12-19

Similar Documents

Publication Publication Date Title
NO20081125L (no) Antitumor middel
NO20081196L (no) Terapeutisk middel for diabetes
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
NO20070323L (no) Organiske forbindelser
HRP20120323T1 (en) Diarylhydantoin compounds
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
BRPI0414271A (pt) aplicação de composições fungicidas para a desinfecção de semente de cereais
MX2009004766A (es) Derivados de espiroindolinona.
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
MY147211A (en) Novel dihydropseudoerythromycin derivatives
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008009831A3 (fr) Derives de cyclodextrines amphiphiles
WO2009064374A8 (en) Oral formulations of bis(thiohydrazide amides)
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
TW200719922A (en) Skin lotion and wrinkle improving agent
EP2308320A3 (en) Hydroxypropylated starch for preventing/treating diabetes
WO2009051223A1 (ja) 白内障処置のための医薬組成物
NO20054787L (no) Indenderivater som farmasotiske midler
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2007025098A3 (en) Triazole compounds and methods of making and using the same
NO20090619L (no) Aminoalkohol-derivatat og immunosuppressiv agent har det samme som en aktive ingrediens
NO20081587L (no) Aerosolformulering for inhalering
TW200621160A (en) Anti-termite agent
AR065597A1 (es) Compuesto ester y su uso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application